Background: Understanding the prescription pattern of antibiotics is crucial for addressing antibiotic resistance and improving public health outcomes. The current survey-based study was intended to gather expert opinions regarding the use of co-amoxiclav in the management of infections in Indian settings.

Methodology: The cross-sectional study utilized an 18-item, multiple-response questionnaire to gather expert opinions from specialists with expertise in managing infections. The survey encompassed questions about current prescription practices, clinical observations, preferences, and experiences related to using co-amoxiclav tablets in the management of infections in routine settings. The data were analyzed using descriptive statistics.

Results: About 83% of clinicians preferred prescribing co-amoxiclav as first-line therapy for respiratory tract infections (RTIs). Most (87.17%) of the clinicians responded that amoxicillin 500 mg + clavulanic acid 125 mg tablet was more effective in treating upper RTIs than other antibiotics. Majority of the experts (94.12%) prescribed co-amoxiclav antibiotics most often for infection in their daily routine practices. Approximately 78% of the clinicians opined that RTIs were the most common type of bacterial infections that were treated with amoxicillin 500 mg + clavulanic acid 125 mg tablets. According to 73% of clinicians, the advantages of amoxicillin + clavulanic acid tablets include broad-spectrum activity, favorable pharmacokinetic profile, and good bacteriological and clinical efficacy.

Conclusion: According to the survey findings, co-amoxiclav was the preferred choice for treating RTIs and other infections due to its broad-spectrum activity, favorable pharmacokinetic profile, and high efficacy.

Manjula S